Geriatric Heart Failure with Preserved Ejection Fraction (HFpEF)

Comprehensive Clinical Guide: Geriatric Heart Failure with Preserved Ejection Fraction (HFpEF)

1. Introduction and Overview

Heart Failure with Preserved Ejection Fraction (HFpEF), historically referred to as diastolic heart failure, has emerged as the most prevalent form of heart failure in the geriatric population. Defined by a left ventricular ejection fraction (LVEF) of ≥50% in the presence of signs and symptoms of heart failure, HFpEF represents a complex clinical syndrome rather than a single disease entity.

In geriatric patients, the condition is uniquely characterized by a convergence of age-related myocardial stiffening, systemic comorbidities, and microvascular inflammation. Unlike Heart Failure with Reduced Ejection Fraction (HFrEF), which is often secondary to ischemic damage or myocardial infarction, HFpEF is a systemic syndrome of aging, frequently driven by hypertension, obesity, chronic kidney disease (CKD), and type 2 diabetes mellitus.

2. Deep-Dive: Pathophysiology and Mechanisms

The pathophysiology of HFpEF in the elderly is multifactorial and distinct from younger cohorts. It is increasingly understood as a "systemic inflammatory state" that affects the myocardium.

The Paradigm of Comorbidities

The prevailing model suggests that systemic comorbidities (obesity, hypertension, diabetes) induce a pro-inflammatory state. This systemic inflammation leads to:
* Coronary Microvascular Endothelial Dysfunction: Reduced nitric oxide bioavailability, which prevents protein kinase G (PKG) activation in cardiomyocytes.
* Myocardial Stiffening: Low PKG activity leads to hypophosphorylation of the giant structural protein titin, resulting in increased myocardial stiffness.
* Fibrosis: Chronic activation of fibroblasts leads to interstitial collagen deposition, further impairing diastolic relaxation and increasing filling pressures.

Hemodynamic Abnormalities

Geriatric patients with HFpEF exhibit:
1. Impaired Diastolic Relaxation: The heart takes longer to relax during diastole, limiting the time available for ventricular filling.
2. Increased Ventricular Stiffness: Small increases in venous return lead to disproportionately high left ventricular end-diastolic pressures (LVEDP).
3. Chronotropic Incompetence: The inability to increase heart rate appropriately during physical exertion is a hallmark, significantly limiting exercise tolerance in the elderly.
4. Vascular Stiffness: Age-related arterial stiffening increases afterload, exacerbating the workload on a non-compliant left ventricle.

3. Clinical Indications, Staging, and Presentation

Standard Clinical Presentation

Geriatric HFpEF often presents with nonspecific symptoms, which can lead to misdiagnosis or delay in care:
* Dyspnea on exertion: The primary complaint, often attributed to "getting older."
* Orthopnea and Paroxysmal Nocturnal Dyspnea (PND): Indicators of fluid overload.
* Fatigue and exercise intolerance: Often severe.
* Peripheral edema: Though sometimes absent if the patient is on strict diuretics.
* Cognitive changes: Reduced cerebral perfusion may manifest as confusion or "brain fog."

Clinical Grading (H2FPEF Score)

To improve diagnostic accuracy, clinicians utilize validated scoring systems like the H2FPEF score:

Interpretation: 0-1 (Low probability), 2-5 (Intermediate), 6-9 (High probability of HFpEF).

4. Differential Diagnosis

Distinguishing HFpEF from other geriatric syndromes is critical. Key differentials include:
* Chronic Obstructive Pulmonary Disease (COPD): Often coexists with HFpEF; pulmonary function testing is required.
* Valvular Heart Disease: Specifically Aortic Stenosis, which can mimic HFpEF symptoms.
* Cardiac Amyloidosis: A critical differential in patients >75 years with significant LV wall thickness and low-voltage ECG.
* Anemia: Frequently exacerbates symptoms in the elderly.
* Deconditioning: Secondary to sedentary lifestyle or musculoskeletal frailty.

5. Diagnostic Testing Protocols

A systematic approach is required to confirm the diagnosis:

1. Biomarkers: NT-proBNP or BNP. Note that these may be falsely low in obese patients, which is common in HFpEF.
2. Echocardiography (The Gold Standard):
   • Assess LVEF (must be ≥50%).
   • Left Atrial Volume Index (LAVI) >34 mL/m² (indicates chronic high filling pressures).
   • E/e' ratio >13 (indicates diastolic dysfunction).
   • Tricuspid Regurgitant Velocity >2.8 m/s.
3. Stress Testing: If resting echoes are inconclusive, exercise stress echocardiography is indicated to reveal the rise in filling pressures during physical activity.
4. Cardiac MRI: Useful for tissue characterization (ruling out infiltrative diseases like amyloidosis).

6. Management, Risks, and Contraindications

Pharmacological Management

• SGLT2 Inhibitors: (e.g., Empagliflozin, Dapagliflozin) are now the cornerstone of therapy. They provide clear mortality and hospitalization benefit in HFpEF.
• Diuretics: Essential for symptom management (loop diuretics like furosemide/torsemide) to control volume status.
• Mineralocorticoid Receptor Antagonists (MRAs): (e.g., Spironolactone) used to reduce hospitalizations, provided potassium and renal function are monitored.
• Blood Pressure Management: Target <130/80 mmHg; however, caution is advised in the "very elderly" (age >85) to prevent orthostatic hypotension and falls.

Risks and Contraindications

• Over-diuresis: Leads to pre-renal azotemia and hypotension, particularly in patients with baseline CKD.
• NSAIDs: Should be avoided as they increase sodium retention and impair renal perfusion.
• Negative Inotropes: Calcium channel blockers (like verapamil/diltiazem) should be used with extreme caution as they may impair diastolic relaxation.

7. Long-term Prognosis

The prognosis for geriatric HFpEF is sobering. Mortality rates are similar to HFrEF, with a 5-year survival rate of approximately 50-60%. Prognosis is dictated not only by cardiac status but by the "frailty index"—a combination of physical, cognitive, and nutritional status. The goal of care is shifting from "mortality reduction" to "maintenance of functional independence and quality of life."

8. FAQ: Frequently Asked Questions

Q1: Why is HFpEF more common in women?
A: Women, particularly post-menopausal women, are more prone to concentric LV hypertrophy and microvascular dysfunction, which are primary drivers of HFpEF.

Q2: Can HFpEF be "cured"?
A: Currently, no. It is a chronic, progressive condition. However, symptoms can be managed effectively with medication, lifestyle modification, and careful fluid management.

Q3: How does obesity affect the diagnosis?
A: Obesity acts as a "double hit." It causes systemic inflammation and also masks findings on echocardiography and lowers BNP levels, making the condition harder to diagnose.

Q4: Are beta-blockers recommended for HFpEF?
A: Beta-blockers are not indicated for mortality reduction in HFpEF unless there is a specific comorbidity like atrial fibrillation or ischemic heart disease.

Q5: What is the role of exercise in geriatric HFpEF?
A: Exercise is vital. Supervised cardiac rehabilitation improves peak VO2 and functional capacity, which are the primary determinants of quality of life in these patients.

Q6: Why is the E/e' ratio important?
A: It provides a non-invasive estimate of LV filling pressures. A high ratio suggests the heart is "stiff" and struggling to relax.

Q7: Is there a specific diet for HFpEF patients?
A: A low-sodium, heart-healthy diet (like the DASH or Mediterranean diet) is recommended to reduce fluid retention and systemic inflammation.

Q8: What is the most common cause of death in HFpEF patients?
A: While cardiovascular death is common, non-cardiovascular causes (infection, renal failure, cancer) are significantly more common in the geriatric HFpEF population than in HFrEF.

Q9: How often should I monitor electrolytes?
A: Because of the high reliance on diuretics, electrolytes (potassium, magnesium) and renal function (creatinine) should be checked regularly, especially when adjusting medication dosages.

Q10: Should I use home blood pressure monitoring?
A: Yes. It is essential for titrating antihypertensive medications and preventing episodes of hypotension, which can lead to falls in the elderly.

9. Conclusion

Geriatric HFpEF is a complex, high-morbidity condition that requires a personalized, multidisciplinary management approach. By focusing on volume management, SGLT2 inhibitor therapy, and the preservation of physical function, clinicians can significantly improve the quality of life for the aging patient. As the global population ages, recognizing HFpEF early—and distinguishing it from simple deconditioning—remains a clinical imperative.